← SynDRA
RILAPLADIB
SynDRA canonical compound SYN0030948 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PLA2G7 |
|---|
| Mechanism of action | phospholipase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PLA2G7 INHIBITOR
- LDL-associated phospholipase A2 inhibitor
- PLA2G7 COMPETITIVE
- phospholipase inhibitor
Cross-references
Synonyms
- SB-659032
- SB 659032
- O14CWE893Z
- rilapladibum
- RefChem:179454
- DTXCID60116772
- Rilapladib (USAN)
- RILAPLADIB [USAN]
- Rilapladib [USAN:INN]
- UNII-O14CWE893Z
- RILAPLADIB [INN]
- GTPL7376
- orb1706716
- SCHEMBL2801812
- C40H38F5N3O3S
- SCHEMBL29359740
- SCHEMBL30644224
- NNBGCSGCRSCFEA-UHFFFAOYSA-N
- GLXC-10594
- HMS3751I15
- EX-A5756
- BDBM50205805
- MFCD13195581
- AKOS027250919
- PB33181
- FR104267
- MS-31278
- DS-002672
- HY-102004
- CS-0022446
- NS00069689
- D05728
- T16751
Look up RILAPLADIB in the interactive SynDRA portal →